pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·50m ago·3 min read
save

Erasca data add to pressure facing Revolution’s breakthrough cancer drug

Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca — which is nearing the start of a Phase 3 trial — may be able to exploit.

Nov 20, 2026·read at BioPharma Dive ↗

An article from Dive Brief Erasca data add to pressure facing Revolution’s breakthrough cancer drug Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca may be able to exploit. Published Nov.

20, 2026 Jonathan Gardner Senior Reporter Share Copy link Email LinkedIn X/Twitter Facebook Print License Add us on Google Dive Brief: Erasca said that 44% of people with KRAS-mutated pancreatic cancer responded to its experimental treatment in a small Phase 1 trial, supporting a decision to quickly advance the medicine into a Phase 3 study. According to Erasca, response rates to its drug ERAS-0015 were even higher — 63% and 80%, respectively — in people with specific KRAS mutations called G12D and G12V. Those genetic signatures cover around two-thirds of people with KRAS-mutated disease.

Side effects were mostly mild, and nobody quit treatment because of them, the company added. While early, the data suggest Erasca’s drug could emerge as a future threat to Revolution Medicines’ breakthrough medicine Rasonque, which has already changed how pancreatic cancer is treated. Revolution’s therapy is already on the market and off to one of the best oncology launches ever.

But Rasonque is associated with frequent skin rashes and its impact on G12D-mutated patients is seen as modest, leaving an opening for competitors to exploit. Dive Insight: Drug research directed at tumors driven by mutations to a family of genes known as “RAS” is advancing quickly. Once seen as “undruggable,” RAS-targeting medicines are now the focus of a constellation of would-be treatments vying to build on Revolution’s success.

Erasca is one of those followers. Like Rasonque, ERAS-0015 is a “molecular glue” that blocks cancer cells from growing and spreading. But it’s designed to have potentially superior characteristics.

Erasca is testing it in pancreatic, biliary tract and non-small cell lung cancers. In initiating coverage of Erasca earlier this week, Leerink Research analyst Asthika Goonewardene wrote that ERAS-0015’s lower side effect rate, if confirmed in additional testing, could offer “opportunities to carve out niches that Rasonque may not be able to access” because of Rasonque’s “overlapping toxicities” with other medicines. Friday’s data offer an early glimpse of that potential.

Unveiled at a medical meeting, the results come from a study of 122 people whose pancreatic cancer had progressed following two or more treatment lines. Study volunteers received daily doses ranging from 16 to 32 milligrams. ERAS-0015’s response rates were higher than what’s been seen in testing of Rasonque.

Revolution’s drug led to treatment responses in 32% of the overall study population and 24% and 50%, respectively, in people with G12D and G12V mutations. Cross-trial comparisons are error-prone, however, and the two drugs haven’t been tested head-to-head. Still, the data suggest ERAS-0015 “could be a formidable competitor in the future, and potentially accelerate the fragmentation of the RAS landscape,” wrote RBC Capital Markets analyst Leonid Timashev, who covers Revolution, in a client note.

The drug “continues to demonstrate a better profile on both efficacy and safety in what was a challenging population — suggesting what may be real differentiation.” TD Cowen analyst Tyler Van Buren disagreed, contending in a separate note that it’s unclear whether the early results will translate to a superior profile in a bigger trial. Oncologists are getting better at managing Rasonque’s side effects, too. Erasca’s data “fail to meaningfully differentiate from Rasonque, especially considering the multi-year commercial head start Rasonque has on nearest competitors,” he wrote.

Revolution, meanwhile, released new data from an early-stage trial testing Rasonque alongside chemotherapy in frontline pancreatic cancer. The combination drove responses in 61% of enrollees, and 8% had no evidence of active disease. Another RAS-focused company, Alterome Therapeutics, presented data from a trial testing its drug ALTA3263 in combination with Erbitux.

The pairing stimulated responses in 31% of people with KRAS-mutated colorectal cancer. Add us on Google Share Copy link Email LinkedIn X/Twitter Facebook Print License Filed Under: Biotech, Clinical Trials

source

Reporting by BioPharma Dive.

read at BioPharma Dive ↗
657 words · retrieved 18m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Erasca, Inc.5Monte Rosa Therapeutics, Inc.
drugs
cetuximab
topics
Oncology11KRAS8Molecular Glue2Colorectal CancerDermatologyPulmonology

related stories

  • Sep 28Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitorBioSpace
  • Dec 22Fierce Biotech Fundraising Tracker '26: VitriVax scores $87M; Ansa adds $71.5M series CFierce Biotech
  • 3h agoRevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early dataBioSpace
  • Oct 14Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggledBioSpace
  • Aug 26Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDABioPharma Dive